Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 20/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 20/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.72 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.72 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377824 | 0.86 | GABRG2 (0.77) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL1379560 | 0.84 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3871681 | 0.81 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2826771 | 0.80 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3871364 | 0.77 | GABRG2 (0.77) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3872472 | 0.77 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL2684162 | 0.77 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3870940 | 0.77 | GABRG2 (0.73) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3873708 | 0.76 | GABRG2 (0.82) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL3872721 | 0.76 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507728-B2 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | claimed |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | US | claimed |
| US-7507728-B2 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA1, GABRA4, GABRA5 | GABRG2 24/4885GABRB3 10/4885GABRA5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.